Brand Name Manufacturers	Depo-Testosterone by Pharmacia/Upjohn
Generic Manufacturers	Geneva Goldline Depotest by Hyrex Rugby Schein Star Steris URL Virilon IM by Star
Pharmacology	Apparently same as endogenous androgens
Delivery	100, 200mg/ml sustained-release intramuscular injection.
Typical dosage	Pre-op 200-300mg/2-3wks Post-op 50-150mg/2-3wks
Availability	Approved by U.S. FDA. Schedule III controlled substance.
Indications	Breast cancer in females. Hormone replacement therapy in males.
Contraindications	Hypersensitivity to any component of the product. Kidney disease. Known or suspected breast cancer.
Adverse reactions	CNS Anxiety. Depression. Headache. Prickling or tingling skin. Gastrointestinal Cholestatic jaundice. Liver tumors and other liver disease. Nausea. Skin Acne. Male pattern baldness. Other Extreme allergic reaction. Increased serum cholesterol. Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Suppression of blood clotting factors.
Comments	Schein/Steris has reportedly discontinued production of injectable testosterone. This action forced up the price of the supply from other manufacturers. See http://www.thegrid.net/ftminfnet/schein.htmlfor more information.
Additional Info:	Depo-Testosterone Patient Information (PDF file on this site)

<< RETURN TO SUMMARY